Euroespes S.A. (EEP) - Total Liabilities
Based on the latest financial reports, Euroespes S.A. (EEP) has total liabilities worth €5.22 Million EUR (≈ $6.10 Million USD) as of December 2022. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Euroespes S.A. (EEP) long-term investment share to see how much of total assets are deployed in long-term investments.
Euroespes S.A. - Total Liabilities Trend (2010–2024)
This chart illustrates how Euroespes S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Euroespes S.A. balance sheet assets.
Euroespes S.A. Competitors by Total Liabilities
The table below lists competitors of Euroespes S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Movinn AS
CO:MOVINN
|
Denmark | Dkr33.67 Million |
|
Autonomix Medical, Inc. Common Stock
NASDAQ:AMIX
|
USA | $818.00K |
|
Madoro Metals Corp
V:MDM
|
Canada | CA$62.26K |
|
iDimension Consolidated Bhd
KLSE:0174
|
Malaysia | RM119.71 Million |
|
Oriental Trimex Limited
NSE:ORIENTALTL
|
India | Rs381.79 Million |
|
Biotron Ltd
AU:BIT
|
Australia | AU$817.93K |
|
DOREL INDS INC. A
F:DO4C
|
Germany | €823.37 Million |
|
International Lithium Corp
V:ILC
|
Canada | CA$306.66K |
Liability Composition Analysis (2010–2024)
This chart breaks down Euroespes S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See EEP equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.38 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Euroespes S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Euroespes S.A. (2010–2024)
The table below shows the annual total liabilities of Euroespes S.A. from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €4.37 Million ≈ $5.11 Million |
-13.27% |
| 2023-12-31 | €5.04 Million ≈ $5.89 Million |
-3.41% |
| 2022-12-31 | €5.22 Million ≈ $6.10 Million |
+8.20% |
| 2021-12-31 | €4.82 Million ≈ $5.64 Million |
+13.31% |
| 2020-12-31 | €4.26 Million ≈ $4.98 Million |
+8.50% |
| 2019-12-31 | €3.92 Million ≈ $4.59 Million |
-0.94% |
| 2018-12-31 | €3.96 Million ≈ $4.63 Million |
-17.11% |
| 2017-12-31 | €4.78 Million ≈ $5.59 Million |
+3.13% |
| 2016-12-31 | €4.63 Million ≈ $5.42 Million |
+26.95% |
| 2015-12-31 | €3.65 Million ≈ $4.27 Million |
+1.71% |
| 2014-12-31 | €3.59 Million ≈ $4.20 Million |
+218.29% |
| 2010-12-31 | €1.13 Million ≈ $1.32 Million |
-- |
About Euroespes S.A.
Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as neuro-ophthalmology, neuro-otorhinolaryngology, neu… Read more